World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 15 September 2020
Main ID:  EUCTR2019-004652-11-SI
Date of registration: 31/08/2020
Prospective Registration: No
Primary sponsor: F. Hoffmann-La Roche Ltd
Public title: A Study of Etrolizumab-Based Induction Therapy Combinations Followed by Etrolizumab Maintenance Therapy in Patients with Moderate-To-Severe Ulcerative Colitis
Scientific title: RANDOMIZED, OPEN-LABEL PHASE 3B STUDY OF ETROLIZUMAB BASED INDUCTION THERAPY COMBINATIONS FOLLOWED BY ETROLIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS - Lantana
Date of first enrolment: 28/08/2020
Target sample size: 372
Recruitment status: Authorised-recruitment may be ongoing or finished
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-004652-11
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: no
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
Number of treatment arms in the trial: 4
 
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no
Countries of recruitment
Argentina Austria Belgium Brazil Canada Czech Republic France Germany
Hungary Ireland Israel Italy Latvia Netherlands Poland Russian Federation
Serbia Slovakia Slovenia Spain Switzerland Turkey Ukraine United Kingdom
United States
Contacts
Name: Trial Information Support Line-TISL   
Address:  Grenzacherstrasse 124 4070 Basel Switzerland
Telephone:
Email: global.rochegenentechtrials@roche.com
Affiliation:  F. Hoffmann-La Roche Ltd
Name: Trial Information Support Line-TISL   
Address:  Grenzacherstrasse 124 4070 Basel Switzerland
Telephone:
Email: global.rochegenentechtrials@roche.com
Affiliation:  F. Hoffmann-La Roche Ltd
Key inclusion & exclusion criteria
Inclusion criteria:
Cohort 1 only
• Age 18-80 years of age, inclusive, at time of signing Informed Consent Form
• Naïve to treatment with infliximab and ustekinumab
• Prior treatment with investigational JAK inhibitors for UC and other investigational treatments for UC (except for investigational anti-integrins) is allowed if discontinued at least 5 drug half-lives prior to randomization
Cohort 2 only
• Age 18-49 years of age, inclusive, at time of signing Informed Consent Form
• Naïve to treatment with tofacitinib
• Prior treatment with infliximab and ustekinumab is allowed if discontinued at least 5 drug half-lives prior to randomization (Day 1), or when serum drug levels of infliximab/ustekinumab are undetectable as measured using a commercial assay (if available), whichever is earlier
• Prior treatment with investigational treatments for UC is allowed if discontinued at least 5 drug half-lives prior to randomization (Day 1)
Cohort 1 and Cohort 2
• Ability to comply with the study protocol, in the investigator's judgment
• Diagnosis of UC established at least 3 months prior to randomization (Day 1) by clinical and endoscopic evidence. This diagnosis should be corroborated by histopathology conducted at any time prior to screening and documented by a histopathology report
• Moderate-to-severely active UC as determined by an mMCS of 4–9, with an endoscopic subscore = 2 as determined by the central reading procedure, a rectal bleeding subscore = 1, and a stool frequency subscore = 1, during the screening period (prior to randomization [Day 1])
• Evidence of UC extending more than 15 cm from the anal verge as determined by baseline endoscopy (flexible sigmoidoscopy or colonoscopy) performed during screening, 4-16 days prior to randomization
• Naïve to treatment with etrolizumab or other anti-integrin agents
• Prior treatment with immunosuppressants (AZA, MTX, or 6-MP) is allowed if discontinued at least 5 drug half-lives (i.e. 5 days) prior to randomization (Day 1)
• Prior treatment with non-infliximab aTNF-a therapy (e.g., adalimumab, golimumab) is allowed if discontinued at least 4 weeks (for adalimumab) or 6 weeks (for golimumab) prior to randomization (Day 1), or when serum drug levels are undetectable as measured using a commercial assay (if available), whichever is earlier
• Patients must not have received more than two biological therapies intended to treat UC prior to Day 1
• Patients must have had an inadequate response, loss of response, or intolerance to prior immunosuppressant and/or corticosteroid treatment
• Any ongoing UC therapy must be at stable doses:
• For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception during the treatment period and for at least 6 months after the final dose of study treatment
• For men who are not surgically sterile: agreement to remain abstinent or use contraception during the treatment period and for at least 6 months after the final dose of study treatment. Men must refrain from donating sperm during this same period.
• Patients must be up-to-date on their colorectal carcinoma (CRC) surveillance according to local standards and guidelines. If patients are not up-to-date, they must be willing to undergo a colonoscopy with appropriate CRC screening biopsies in lieu of a flexible sigmoidoscopy at screening



Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes

Exclusion criteria:
Inflammatory Bowel Disease
Cohort 1+2:
• Prior extensive colonic resection, subtotal or total colectomy, or planned surgery for UC
• Past or present ileostomy or colostomy
• Diagnosis of indeterminate colitis
• Suspicion of ischemic colitis, radiation colitis, or microscopic colitis
• Diagnosis of toxic megacolon within 12 months of initial screening visit
• Any diagnosis of Crohn’s disease
• Past or present fistula or abdominal abscess
• Current evidence of colonic mucosal dysplasia or history of colonic mucosal dysplasia within 5 years prior to inclusion
• Patients with any stricture (stenosis) of the colon
• Patients with history or evidence of adenomatous colonic polyps that have not been removed
Exclusion Criteria Related to Prior or Concomitant Therapy
Cohort 1 only
• Any prior treatment with infliximab or ustekinumab
Cohort 2 only
• Any prior treatment with tofacitinib
• Prior treatment with investigational JAK inhibitors for UC
• Receiving treatment with single or combined hormonal contraception therapy
• Current treatment with potent inhibitors of CYP3A4 or receiving one or more concomitant medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 that would increase serum availability of tofacitinib
Cohort 1+2
• Any prior treatment with etrolizumab or other anti-integrin agents
• Any prior treatment with anti-adhesion molecules
• Receiving treatment with immunosuppressants (AZA, 6-MP, or MTX) within the 5 drug half-lives(ie. 5 days) prior to Day 1
• Use of IV steroids within 30 days prior to screening with the exception of a single administration of IV steroid
• Use of agents that deplete B or T cells within 12 months prior to randomization, with the exception of AZA and 6-MP (which must be discontinued 5 half-lives (i.e. 5 days) prior to Day 1 )
• Use of cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil (MMF) within 4 weeks prior to randomization
• Chronic nonsteroidal anti-inflammatory drug (NSAID) use
• Patients who are currently using anticoagulants
• Patients who have received treatment with corticosteroid enemas/suppositories and/or topical (rectal) 5-ASA preparations within 2 weeks prior to randomization
• Apheresis within 2 weeks prior to randomization
• Received any investigational treatment including investigational vaccines within 5 half-lives of the investigational product or 28 days after the last dose (whichever is greater) prior to randomization
• History of moderate or severe allergic or anaphylactic/anaphylactoid or hypersensitivity reactions to chimeric, human, or humanized antibodies, fusion proteins, or murine proteins
• Patients administered tube feeding, defined formula diets, or parenteral alimentation/nutrition who have not discontinued these treatments = 3 weeks prior to randomization
Exclusion Criteria related to General Safety
Cohort 1 only
• History of moderate-to-severe heart failure New York Heart Association [NYHA] Class III/IV
Cohort 2 only
• History of heart failure
• Patients with inherited coagulation disorders
• History of venous thromboembolism, either deep venous thrombosis or pulmonary embolism
• Patients undergoing major surgery
Cohort 1+2
• Lack of peripheral venous access
• Significant uncontrolled comorbidity
• Neurological conditions or diseases that may interfere with monitoring for PML
• History of demyelinating disease
• Clinically significant abnormalities on screening neurologic ex


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Ulcerative Colitis (UC)
MedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 100000004856
Intervention(s)

Product Name: Etrolizumab
Product Code: RO5490261/F04-02
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: Etrolizumab
CAS Number: 1044758-60-2
Current Sponsor code: RO5490261
Other descriptive name: rhuMAb Beta7, Anti Beta7, PRO145223
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 105-

Trade Name: Remicade
Pharmaceutical Form: Powder for concentrate for solution for infusion
INN or Proposed INN: INFLIXIMAB
CAS Number: 170277-31-3
Current Sponsor code: RO6897845
Other descriptive name: INFLIXIMAB
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-

Trade Name: Xeljanz
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: TOFACITINIB
CAS Number: 477600-75-2
Current Sponsor code: Ro 516-9503
Other descriptive name: TOFACITINIB
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-

Trade Name: Xeljanz
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: TOFACITINIB
CAS Number: 477600-75-2
Current Sponsor code: Ro 516-9503
Other descriptive name: TOFACITINIB
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-

Trade Name: Stelara
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: USTEKINUMAB
CAS Number: 815610-63-0
Current Sponsor code: Ro 723-3920
Other descriptive name: USTEKINUMAB
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 5-

Trade Name: Stelara
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: USTEKINUMAB
CAS Number: 815610-63-0
Current Sponsor code: Ro 723-3920
Other descriptive name: USTEKINUMAB
Concentration unit: mg/ml milligram(s)/millilitre
Concentra
Primary Outcome(s)
Main Objective: • To evaluate the efficacy of induction therapy with etrolizumab-based combinations compared to etrolizumab monotherapy, assessed as corticosteroid-free endoscopic improvement at Week 14
Primary end point(s): 1. Corticosteroid-free endoscopic improvement at Week 14
Secondary Objective: • Induction of corticosteroid-free: remission, clinical response, endoscopic remission, histologic remission, symptomatic remission, rectal bleeding score 0, remission at Week 14 in patients receiving corticosteroids at baseline
• Change in UC- Patient-Reported outcome (PRO) signs/symptoms and UC/PROs related to various aspects of QoL (quality of life) (induction and maintenance phase)
• Remission at Week 54 among patients with clinical response and remission at Week 14, respectively
• Endoscopic remission at Week 54 among patients in endoscopic remission and endoscopic improvement at Week 14, respectively
• Histologic remission at Week 54
• Corticosteroid-free remission at Week 54 in patients who were in corticosteroid-free remission at Week 14.
• Overall safety and tolerability of etrolizumab-based combinations compared to etrolizumab monotherapy
• The incidence and severity of immunosuppression-related adverse events and hypersensitivity reactions
Timepoint(s) of evaluation of this end point: 1. Week 14
Secondary Outcome(s)
Secondary end point(s): 1. To evaluate induction of corticosteroid-free remission at Week 14, as assessed by the mMCS
2. To evaluate corticosteroid-free clinical response at Week 14, as assessed by the mMCS
3. To evaluate corticosteroid-free endoscopic remission at Week 14
4. To evaluate corticosteroid-free histologic remission at Week 14
5. To evaluate corticosteroid-free symptomatic remission at Week 14
6. To evaluate onset of action, defined as time to rectal bleeding score of 0
7. To evaluate onset of action, defined as change from baseline (Day 1) in stool frequency subscore at Week 2, Week 4, and Week 6
8. To evaluate change in UC bowel movement signs and symptoms from baseline (Day 1) to Week 14, as assessed by the Ulcerative Colitis-Patient-Reported Outcome Signs and Symptoms (UC-PRO/SS) measure
9. To evaluate change in UC functional symptoms from baseline (Day 1) to Week 14, as assessed by the UC-PRO/SS measure
10. To evaluate change in UC systemic symptoms from baseline (Day 1) to Week 14, as assessed by the UC-PRO Systemic Symptoms measure
11. To evaluate change in UC daily coping strategies, daily life impact, and emotional impact from baseline (Day 1) to Week 14, as assessed by the UC-PRO Daily Coping (UC-PRO-DC), UC-PRO Daily Life Impact (UC-PRO-DLI), and UC-PRO Emotional Impact (UC-PRO-EI) measures
12. To evaluate change from baseline (Day 1) in patient-reported health-related quality of life at Week 14, as assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ)
13. To evaluate corticosteroid-free remission at Week 14 (off corticosteroid for at least 4 weeks prior to Week 14) in patients who were receiving corticosteroids at baseline (Day 1), as assesses by mMCS
14. To evaluate remission at Week 54 among patients with clinical response at Week 14
15. To evaluate remission at Week 54 among patients in remission at Week 14
16. To evaluate endoscopic remission at Week 54 among patients in endoscopic remission at Week 14
17. To evaluate endoscopic remission at Week 54 among patients with endoscopic improvement at Week 14
18. To evaluate histologic remission at Week 54
19. To evaluate corticosteroid-free remission at Week 54 in patients who were in corticosteroid-free remission at Week 14
20. To evaluate corticosteroid-free (at least 24 consecutive weeks during maintenance) remission at Week 54 among patients who were in corticosteroid-free remission at Week 14
21. To evaluate symptomatic remission at Week 54 among patients with clinical response at Week 14
22. To evaluate change in UC bowel movement signs and symptoms from baseline (Day 1) to Week 14 and Week 14 to Week 54, as assessed by the UC-PRO/SS measure
23. To evaluate change in UC functional symptoms from baseline (Day 1) to Week 14 and Week 14 to Week 54, as assessed by the UC-PRO/SS measure
24. To evaluate change in UC systemic symptoms from baseline (Day 1) to Week 14 and Week 14 to Week 54, as assessed by the UC-PRO Systemic Symptoms measure
25. To evaluate change in UC daily coping strategies, daily life impact, and emotional impact from baseline (Day 1) to Week 14 and Week 14 to Week 54, as assessed by the UC-PRO Daily Coping (UC-PRO-DC), UC-PRO Daily Life Impact (UC-PRO-DLI), and UC-PRO Emotional Impact (UC-PRO-EI) measures
26. To evaluate change in patient-reported health related quality of life from baseline (Day 1) to Week 14 and Week 14 to Week 54, as assessed by the IBDQ
27. To evaluate the overall safety and tolerability of etrolizumab-based combinations compared to etrolizumab monotherapy
28. To evaluate the incidence and severity of immunosuppression-related adverse events
29. To evaluate the incidence and severity of hypersensitivity reactions
Timepoint(s) of evaluation of this end point: 1-5. Week 14
6. Up to Week 54
7. Week 2, Week 4, and Week 6
8-13. Baseline (Day 1) to Week 14
14-21. Week 14, Week 54
22-26. Baseline to Week 14 and Week 14 to Week 54
27-29. Up to Week 66
Secondary ID(s)
MA41419
Source(s) of Monetary Support
F. Hoffmann-La Roche Ltd
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 23/07/2020
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history